Risks and benefits of percutaneous biopsy and primary chemotherapy in advanced Wilms' tumour
Between 1982 and 1988, 36 children with advanced Wilms' tumour underwent percutaneous trucut needle biopsy followed by chemotherapy before definitive surgery. Nephrectomy was performed after a median of 14 weeks of chemotherapy. Substantial reduction in tumour bulk was achieved in 94% of patien...
Gespeichert in:
| Veröffentlicht in: | Journal of pediatric surgery 1991-05, Vol.26 (5), p.610-612 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 612 |
|---|---|
| container_issue | 5 |
| container_start_page | 610 |
| container_title | Journal of pediatric surgery |
| container_volume | 26 |
| creator | Dykes, E.H. Marwaha, R.K. Dicks-Mireaux, C. Sams, V. Risdon, R.A. Duffy, P.G. Ransley, P.G. Pritchard, J. |
| description | Between 1982 and 1988, 36 children with advanced Wilms' tumour underwent percutaneous trucut needle biopsy followed by chemotherapy before definitive surgery. Nephrectomy was performed after a median of 14 weeks of chemotherapy. Substantial reduction in tumour bulk was achieved in 94% of patients. Biopsy morbidity was low and complete concordance between the histological assessment of the tumour in the biopsy specimen and at subsequent nephrectomy was confirmed in 26 of 28 (93%) patients. The overall clinical value of trucut biopsy was 83% (
30
36
patients). Survival rates in this high-risk group were comparable to those of children with less advanced disease. Chemotherapy may be the primary treatment of choice for patients with Wilms' tumour. Percutaneous biopsy allows definition of histology in most patients without increasing morbidity. |
| doi_str_mv | 10.1016/0022-3468(91)90719-A |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80655563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>002234689190719A</els_id><sourcerecordid>80655563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-4d323f1e3435072192f321f536fe40a66f873166e371be3011f4f3e7c8ab213</originalsourceid><addsrcrecordid>eNp9kMtKxTAQhoMoery8gUIW4mVRzSRt2m6Eg3gDQVDBjRDSdILR3kxa4by9PfagO1cDM98_zHyE7AM7AwbynDHOIxHL7CSH05ylkEfzNTKDRECUMJGuk9kvskW2Q3hnbGwz2CSbIOMMeDYjr48ufASqm5IW2KB1faCtpR16M_S6wXYItHBtFxY_TOddrf2Cmjes2_4Nve4W1DVUl1-6MVjSF1fV4Zj2Q90OfpdsWF0F3FvVHfJ0ffV8eRvdP9zcXc7vIyMy2UdxKbiwgCIWCUs55NwKDjYR0mLMtJQ2SwVIiSKFAgUDsLEVmJpMFxzEDjmatna-_Rww9Kp2wWBVTeerjMkkSaQYwXgCjW9D8GjV6h0FTC2VqqUvtfSlclA_StV8jB2s9g9FjeVfaHI4zg9Xcx2MrqwfTbjwiyU8jXMmR-xiwnA08eXQq2AcLqU5j6ZXZev-v-Mbb8qR7A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80655563</pqid></control><display><type>article</type><title>Risks and benefits of percutaneous biopsy and primary chemotherapy in advanced Wilms' tumour</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Dykes, E.H. ; Marwaha, R.K. ; Dicks-Mireaux, C. ; Sams, V. ; Risdon, R.A. ; Duffy, P.G. ; Ransley, P.G. ; Pritchard, J.</creator><creatorcontrib>Dykes, E.H. ; Marwaha, R.K. ; Dicks-Mireaux, C. ; Sams, V. ; Risdon, R.A. ; Duffy, P.G. ; Ransley, P.G. ; Pritchard, J.</creatorcontrib><description>Between 1982 and 1988, 36 children with advanced Wilms' tumour underwent percutaneous trucut needle biopsy followed by chemotherapy before definitive surgery. Nephrectomy was performed after a median of 14 weeks of chemotherapy. Substantial reduction in tumour bulk was achieved in 94% of patients. Biopsy morbidity was low and complete concordance between the histological assessment of the tumour in the biopsy specimen and at subsequent nephrectomy was confirmed in 26 of 28 (93%) patients. The overall clinical value of trucut biopsy was 83% (
30
36
patients). Survival rates in this high-risk group were comparable to those of children with less advanced disease. Chemotherapy may be the primary treatment of choice for patients with Wilms' tumour. Percutaneous biopsy allows definition of histology in most patients without increasing morbidity.</description><identifier>ISSN: 0022-3468</identifier><identifier>EISSN: 1531-5037</identifier><identifier>DOI: 10.1016/0022-3468(91)90719-A</identifier><identifier>PMID: 1648128</identifier><identifier>CODEN: JPDSA3</identifier><language>eng</language><publisher>Philadelphia, PA: Elsevier Inc</publisher><subject>Adolescent ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biopsy, Needle - adverse effects ; Child ; Child, Preschool ; Combined Modality Therapy ; Dactinomycin - administration & dosage ; Doxorubicin - administration & dosage ; Female ; Humans ; Infant ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - mortality ; Kidney Neoplasms - pathology ; Kidney Neoplasms - surgery ; Male ; Medical sciences ; Nephrectomy ; Nephrology. Urinary tract diseases ; preoperative chemotherapy ; Survival Rate ; trucut biopsy ; Vincristine - administration & dosage ; Wilms Tumor - drug therapy ; Wilms Tumor - mortality ; Wilms Tumor - pathology ; Wilms Tumor - surgery ; Wilms' tumor</subject><ispartof>Journal of pediatric surgery, 1991-05, Vol.26 (5), p.610-612</ispartof><rights>1991</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-4d323f1e3435072192f321f536fe40a66f873166e371be3011f4f3e7c8ab213</citedby><cites>FETCH-LOGICAL-c386t-4d323f1e3435072192f321f536fe40a66f873166e371be3011f4f3e7c8ab213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/002234689190719A$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5274906$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1648128$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dykes, E.H.</creatorcontrib><creatorcontrib>Marwaha, R.K.</creatorcontrib><creatorcontrib>Dicks-Mireaux, C.</creatorcontrib><creatorcontrib>Sams, V.</creatorcontrib><creatorcontrib>Risdon, R.A.</creatorcontrib><creatorcontrib>Duffy, P.G.</creatorcontrib><creatorcontrib>Ransley, P.G.</creatorcontrib><creatorcontrib>Pritchard, J.</creatorcontrib><title>Risks and benefits of percutaneous biopsy and primary chemotherapy in advanced Wilms' tumour</title><title>Journal of pediatric surgery</title><addtitle>J Pediatr Surg</addtitle><description>Between 1982 and 1988, 36 children with advanced Wilms' tumour underwent percutaneous trucut needle biopsy followed by chemotherapy before definitive surgery. Nephrectomy was performed after a median of 14 weeks of chemotherapy. Substantial reduction in tumour bulk was achieved in 94% of patients. Biopsy morbidity was low and complete concordance between the histological assessment of the tumour in the biopsy specimen and at subsequent nephrectomy was confirmed in 26 of 28 (93%) patients. The overall clinical value of trucut biopsy was 83% (
30
36
patients). Survival rates in this high-risk group were comparable to those of children with less advanced disease. Chemotherapy may be the primary treatment of choice for patients with Wilms' tumour. Percutaneous biopsy allows definition of histology in most patients without increasing morbidity.</description><subject>Adolescent</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biopsy, Needle - adverse effects</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Combined Modality Therapy</subject><subject>Dactinomycin - administration & dosage</subject><subject>Doxorubicin - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - mortality</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidney Neoplasms - surgery</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nephrectomy</subject><subject>Nephrology. Urinary tract diseases</subject><subject>preoperative chemotherapy</subject><subject>Survival Rate</subject><subject>trucut biopsy</subject><subject>Vincristine - administration & dosage</subject><subject>Wilms Tumor - drug therapy</subject><subject>Wilms Tumor - mortality</subject><subject>Wilms Tumor - pathology</subject><subject>Wilms Tumor - surgery</subject><subject>Wilms' tumor</subject><issn>0022-3468</issn><issn>1531-5037</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKxTAQhoMoery8gUIW4mVRzSRt2m6Eg3gDQVDBjRDSdILR3kxa4by9PfagO1cDM98_zHyE7AM7AwbynDHOIxHL7CSH05ylkEfzNTKDRECUMJGuk9kvskW2Q3hnbGwz2CSbIOMMeDYjr48ufASqm5IW2KB1faCtpR16M_S6wXYItHBtFxY_TOddrf2Cmjes2_4Nve4W1DVUl1-6MVjSF1fV4Zj2Q90OfpdsWF0F3FvVHfJ0ffV8eRvdP9zcXc7vIyMy2UdxKbiwgCIWCUs55NwKDjYR0mLMtJQ2SwVIiSKFAgUDsLEVmJpMFxzEDjmatna-_Rww9Kp2wWBVTeerjMkkSaQYwXgCjW9D8GjV6h0FTC2VqqUvtfSlclA_StV8jB2s9g9FjeVfaHI4zg9Xcx2MrqwfTbjwiyU8jXMmR-xiwnA08eXQq2AcLqU5j6ZXZev-v-Mbb8qR7A</recordid><startdate>19910501</startdate><enddate>19910501</enddate><creator>Dykes, E.H.</creator><creator>Marwaha, R.K.</creator><creator>Dicks-Mireaux, C.</creator><creator>Sams, V.</creator><creator>Risdon, R.A.</creator><creator>Duffy, P.G.</creator><creator>Ransley, P.G.</creator><creator>Pritchard, J.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19910501</creationdate><title>Risks and benefits of percutaneous biopsy and primary chemotherapy in advanced Wilms' tumour</title><author>Dykes, E.H. ; Marwaha, R.K. ; Dicks-Mireaux, C. ; Sams, V. ; Risdon, R.A. ; Duffy, P.G. ; Ransley, P.G. ; Pritchard, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-4d323f1e3435072192f321f536fe40a66f873166e371be3011f4f3e7c8ab213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adolescent</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biopsy, Needle - adverse effects</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Combined Modality Therapy</topic><topic>Dactinomycin - administration & dosage</topic><topic>Doxorubicin - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - mortality</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidney Neoplasms - surgery</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nephrectomy</topic><topic>Nephrology. Urinary tract diseases</topic><topic>preoperative chemotherapy</topic><topic>Survival Rate</topic><topic>trucut biopsy</topic><topic>Vincristine - administration & dosage</topic><topic>Wilms Tumor - drug therapy</topic><topic>Wilms Tumor - mortality</topic><topic>Wilms Tumor - pathology</topic><topic>Wilms Tumor - surgery</topic><topic>Wilms' tumor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dykes, E.H.</creatorcontrib><creatorcontrib>Marwaha, R.K.</creatorcontrib><creatorcontrib>Dicks-Mireaux, C.</creatorcontrib><creatorcontrib>Sams, V.</creatorcontrib><creatorcontrib>Risdon, R.A.</creatorcontrib><creatorcontrib>Duffy, P.G.</creatorcontrib><creatorcontrib>Ransley, P.G.</creatorcontrib><creatorcontrib>Pritchard, J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pediatric surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dykes, E.H.</au><au>Marwaha, R.K.</au><au>Dicks-Mireaux, C.</au><au>Sams, V.</au><au>Risdon, R.A.</au><au>Duffy, P.G.</au><au>Ransley, P.G.</au><au>Pritchard, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risks and benefits of percutaneous biopsy and primary chemotherapy in advanced Wilms' tumour</atitle><jtitle>Journal of pediatric surgery</jtitle><addtitle>J Pediatr Surg</addtitle><date>1991-05-01</date><risdate>1991</risdate><volume>26</volume><issue>5</issue><spage>610</spage><epage>612</epage><pages>610-612</pages><issn>0022-3468</issn><eissn>1531-5037</eissn><coden>JPDSA3</coden><abstract>Between 1982 and 1988, 36 children with advanced Wilms' tumour underwent percutaneous trucut needle biopsy followed by chemotherapy before definitive surgery. Nephrectomy was performed after a median of 14 weeks of chemotherapy. Substantial reduction in tumour bulk was achieved in 94% of patients. Biopsy morbidity was low and complete concordance between the histological assessment of the tumour in the biopsy specimen and at subsequent nephrectomy was confirmed in 26 of 28 (93%) patients. The overall clinical value of trucut biopsy was 83% (
30
36
patients). Survival rates in this high-risk group were comparable to those of children with less advanced disease. Chemotherapy may be the primary treatment of choice for patients with Wilms' tumour. Percutaneous biopsy allows definition of histology in most patients without increasing morbidity.</abstract><cop>Philadelphia, PA</cop><pub>Elsevier Inc</pub><pmid>1648128</pmid><doi>10.1016/0022-3468(91)90719-A</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3468 |
| ispartof | Journal of pediatric surgery, 1991-05, Vol.26 (5), p.610-612 |
| issn | 0022-3468 1531-5037 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80655563 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biopsy, Needle - adverse effects Child Child, Preschool Combined Modality Therapy Dactinomycin - administration & dosage Doxorubicin - administration & dosage Female Humans Infant Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Kidney Neoplasms - pathology Kidney Neoplasms - surgery Male Medical sciences Nephrectomy Nephrology. Urinary tract diseases preoperative chemotherapy Survival Rate trucut biopsy Vincristine - administration & dosage Wilms Tumor - drug therapy Wilms Tumor - mortality Wilms Tumor - pathology Wilms Tumor - surgery Wilms' tumor |
| title | Risks and benefits of percutaneous biopsy and primary chemotherapy in advanced Wilms' tumour |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T15%3A51%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risks%20and%20benefits%20of%20percutaneous%20biopsy%20and%20primary%20chemotherapy%20in%20advanced%20Wilms'%20tumour&rft.jtitle=Journal%20of%20pediatric%20surgery&rft.au=Dykes,%20E.H.&rft.date=1991-05-01&rft.volume=26&rft.issue=5&rft.spage=610&rft.epage=612&rft.pages=610-612&rft.issn=0022-3468&rft.eissn=1531-5037&rft.coden=JPDSA3&rft_id=info:doi/10.1016/0022-3468(91)90719-A&rft_dat=%3Cproquest_cross%3E80655563%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80655563&rft_id=info:pmid/1648128&rft_els_id=002234689190719A&rfr_iscdi=true |